Johnson R W, Webb N J, Lewis M A, Postlethwaite R J, Dyer P A, Connolly J K
North West Regional Transplant Service, Manchester Royal Infirmary, England, United Kingdom.
Kidney Int Suppl. 1996 Jan;53:S72-6.
This report deals with 120 cadaveric renal transplants performed in 101 pediatric recipients in this Centre in two five-year periods, 1984 to 1988 (N = 65) and 1989 to 1993 (N = 55). In the first group transplants were allocated on the basis of best size (small donors for small recipients); in the second group priority was given to beneficial HLA matching. Initial immunosuppression was either cyclosporine (CsA) monotherapy (15 mg/kg/day), or triple therapy (CsA 5 mg/kg/day, prednisolone 1 mg/kg/day and azathioprine 1 mg/kg/day) if there was delayed graft function. Patient survival at one year and five years (97.5% and 92.3%, respectively) did not differ between the two groups, although there was an improvement in graft survival at one and five years in the second period relative to the first: 69.2% and 53.8% versus 78.6% and 65.6%. This did not achieve statistical significance. One year graft survival in recipients under five years did not differ significantly from older children (72%). There was a trend to improvement in one year graft survival in the < five years of age pediatric patients in Group 2, with beneficially matched kidneys and improved immunosuppressive management. Graft losses due to acute rejection were similar in both groups. Donor age < 4 years significantly reduced one year graft survival (63% vs. 85%, P = 0.01), while recipient age had no effect. Small donor kidneys were associated with a higher incidence of graft thrombosis. Transplantation resulted in the normalization or acceleration of growth velocity in (84%) of the pre-pubertal children who completed follow up. In conclusion, we have shown that excellent patient and graft survival can be achieved in children transplanted under the age of five years. Kidneys from donors under the age of four years are associated with an unacceptable rate of graft loss. Small children do not readily accept cyclosporine monotherapy. Successful early renal transplantation offers the best chance of normal growth and development.
本报告涉及本中心在两个五年期内为101名儿科受者进行的120例尸体肾移植手术,即1984年至1988年(N = 65)和1989年至1993年(N = 55)。在第一组中,根据最佳尺寸分配移植肾(小供体给小受者);在第二组中,优先考虑有益的HLA配型。初始免疫抑制采用环孢素(CsA)单一疗法(15毫克/千克/天),如果出现移植肾功能延迟,则采用三联疗法(CsA 5毫克/千克/天、泼尼松龙1毫克/千克/天和硫唑嘌呤1毫克/千克/天)。两组患者的一年和五年生存率(分别为97.5%和92.3%)没有差异,尽管相对于第一期,第二期的一年和五年移植肾生存率有所提高:分别为69.2%和53.8%,而第一期为78.6%和65.6%。但这未达到统计学意义。五岁以下受者的一年移植肾生存率与大龄儿童没有显著差异(72%)。在第二组五岁以下的儿科患者中,由于肾配型有益且免疫抑制管理得到改善,一年移植肾生存率有提高的趋势。两组因急性排斥导致的移植肾丢失情况相似。供体年龄<4岁显著降低了一年移植肾生存率(63%对85%,P = 0.01),而受者年龄则无影响。小供体肾与移植肾血栓形成的发生率较高有关。移植使完成随访的青春期前儿童中84%的生长速度恢复正常或加快。总之,我们已经表明,五岁以下儿童接受肾移植可以获得优异的患者和移植肾生存率。四岁以下供体的肾与不可接受的移植肾丢失率相关。幼儿不容易接受环孢素单一疗法。早期成功的肾移植为正常生长发育提供了最佳机会。